Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial

Published:2014-04 Issue:2 Volume:5 Page:119-126
ISSN:1879-4068
Container-title:Journal of Geriatric Oncology
language:en
Short-container-title:Journal of Geriatric Oncology

Author:

Horgan Anne M.,Seruga Bostjan,Pond Greg R.,Alibhai Shabbir M.,Amir Eitan,De Wit Ronald,Eisenberger Mario A.,Tannock Ian F.

Publisher

Elsevier BV

Subject

Geriatrics and Gerontology,Oncology

Reference19 articles.

1. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study;Berthold;J Clin Oncol,2008

4. Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer;Shepard;J Clin Oncol,2010

5. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer;Italiano;Eur Urol,2009

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TOward a comPrehensive supportive Care intervention for Older men with metastatic Prostate cancer (TOPCOP3): A pilot randomized controlled trial and process evaluation;Journal of Geriatric Oncology;2024-07

2. Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology;Current Oncology;2024-02-15

3. Systemtherapie des Prostatakarzinoms im hohen Alter;Die Onkologie;2024-01-26

4. Prostate Cancer;Geriatric Medicine;2024

5. Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer;JAMA Oncology;2023-12-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3